@prefix this: <http://www.tkuhn.ch/bel2nanopub/RAQfV5-xLlpw3kxtvQ4VjUdtLbOMXTLLzcIv2KILNHN2Q> .
@prefix sub: <http://www.tkuhn.ch/bel2nanopub/RAQfV5-xLlpw3kxtvQ4VjUdtLbOMXTLLzcIv2KILNHN2Q#> .
@prefix beldoc: <http://resource.belframework.org/belframework/1.0/knowledge/large_corpus.bel> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix dct: <http://purl.org/dc/terms/> .
@prefix dce: <http://purl.org/dc/elements/1.1/> .
@prefix pav: <http://purl.org/pav/> .
@prefix np: <http://www.nanopub.org/nschema#> .
@prefix belv: <http://www.selventa.com/vocabulary/> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix hgnc: <http://www.genenames.org/cgi-bin/gene_symbol_report?hgnc_id=> .
@prefix proteinModification: <http://www.ebi.ac.uk/ontology-lookup/?termId=MOD:00000> .
@prefix psimod: <http://www.ebi.ac.uk/ontology-lookup/?termId=MOD:> .
@prefix mesh: <http://purl.bioontology.org/ontology/MSH/> .
@prefix species: <http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id=> .
@prefix occursIn: <http://purl.obolibrary.org/obo/BFO_0000066> .
@prefix pubmed: <http://www.ncbi.nlm.nih.gov/pubmed/> .
@prefix orcid: <http://orcid.org/> .

sub:Head {
  this: np:hasAssertion sub:assertion;
    np:hasProvenance sub:provenance;
    np:hasPublicationInfo sub:pubinfo;
    a np:Nanopublication .
}

sub:assertion {
  sub:_1 belv:variantOf hgnc:936;
    a proteinModification:, psimod:00696 .
  
  sub:_2 occursIn: mesh:D001940, mesh:D003106, species:9606;
    rdf:object mesh:D017209;
    rdf:predicate belv:decreases;
    rdf:subject sub:_1;
    a rdf:Statement .
  
  sub:assertion rdfs:label "p(HGNC:BAD,pmod(P,S)) -| bp(MESHPP:Apoptosis)" .
}

sub:provenance {
  beldoc: dce:description "Approximately 61,000 statements.";
    dce:rights "Copyright (c) 2011-2012, Selventa. All rights reserved.";
    dce:title "BEL Framework Large Corpus Document";
    pav:authoredBy sub:_4;
    pav:version "1.4" .
  
  sub:_3 prov:value "STATs are important regulators of breast development and carcinogenesis. Constitutively elevated STAT DNA-binding activity is seen in primary breast tumor specimens from patients with advanced disease compared to adjacent nontumor tissues Constitutively active STAT3 mediates oncogenic transformation in immortalized fi- broblasts and induces tumor formation in nude mice, suggesting a pivotal role of STAT3 in transformation (48) Berclaz et al. found a very strong correlation between nuclear STAT3 andEGFRexpression in breast cancers cells. ProstaglandinHsynthetases (composed of Cox- 1 and Cox-2 isoenzymes) convert arachidonic acid into prostaglandins that are further modified to produce important signal molecules Induced Cox-2 expression is seen in almost all tumor sites. It was shown over a decade ago that both PGE1 and PGE2 enhance mitogenesis in mammary epithelial cells stimulated with EGF (165,166). In Hs578T breast cancer cells, Cox-2 expression is related to digestion of basement membrane, resulting in cellular invasiveness (167). Cox-2 expression is seen in the majority of HER2-overexpressing breast cancers, and in a small fraction of HER2-negative breast cancers as well (164) Posttranslational farnesylation is required for Ras to function in the inner membrane surface, a process catalyzed by farnesyl transferase. Substrates for this enzyme include all four Ras proteins as well as other non-Ras proteins (e.g., RhoB) that have the amino acid CAAX motif where X represents methionine or serine A direct role of Raf in the development of human cancers is well documented in literature (161). In MCF-7 cells, Raf-1 and A-Raf are upregulated after treatment with (-) estradiol, but not in ER-negative cells. Overexpression of constitutively active Raf-1 causes cell cycle progression and results in an increased proliferative response to (-) estradiol (273). Raf-1 protein is overexpressed in the cytosol fraction of human breast cancer tissues but not in normal mammary gland tissue ( Geldanamycin, herbimycin A, 17-allylaminogeldanamycin (17-AAG), radicicol, KF25706, and KF58333 represent a class of compounds that bind to heat-shock protein-90 (Hsp90) (Table II). They destabilize Hsp90-associating proteins including Raf- 1, ErbB2, Akt, p53, v-Src, Bcr-Abl, HIF-1a, ER, PR, and glucocorticoid receptors (277). Hence, geldanamycin and its analogs are not specific for any one target. Geldanamycin causes destabilization of Raf- 1 and loss of Raf-1-Ras association, the Raf-MEKMAPK signaling pathway (278,279). Geldanamycin increases the recruitment of chaperone-interacting protein (CHIP), which is known to efficiently ubiquitinate and down-regulate ErbB2 in COS7 cells (280). KF58333, an oxime derivative of radicicol, is a potent growth inhibitor of high- and low-Her2 expressing breast cell lines (212). 17-AAG, a geldanamycin analog, has less toxicity than its predecessor and is able to downregulate Akt expression, inhibit PI3K and Akt activity, suppress cyclin D expression, and ultimately inhibit growth of HER2-overexpressing breast cancer It has been shown that Akt has antiapoptosis effect by phosphorylating Bad and other death proteins (285-287). Akt";
    prov:wasQuotedFrom pubmed:14587863 .
  
  sub:_4 rdfs:label "Selventa" .
  
  sub:assertion prov:hadPrimarySource pubmed:14587863;
    prov:wasDerivedFrom beldoc:, sub:_3 .
}

sub:pubinfo {
  this: dct:created "2014-07-03T14:30:17.929+02:00"^^xsd:dateTime;
    pav:createdBy orcid:0000-0001-6818-334X, orcid:0000-0002-1267-0234 .
}